Swiss molecular diagnostics firm Biocartis said last week that it is collaborating with the Wellcome Trust Sanger Institute and Philips Research to develop a workflow to extract and amplify circulating tumor DNA from blood samples for downstream analysis on Biocartis' multiplex d
NEW YORK (GenomeWeb News) – Biocartis today announced it is developing a workflow for extracting, amplifying, and detecting tumor DNA on its diagnostic platforms in collaboration with the Wellcome Trust Sanger Institute and Philips Research.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Swiss molecular diagnostics company Biocartis today announced it has completed its Series C equity financing round, raising €71 million ($96 million).
The trials, expected to begin in the second half of this year, will be for its benchtop automated DNA-testing platform and its first cartridge-based test for multiple causative agents of pneumonia and antibiotic-resistance markers.
Diagnoplex received a boost toward commercializing its flagship PCR-based colon cancer blood test in the form of a "substantial" Series A financing extension by fellow Swiss biopharmaceutical conglomerate Debiopharm Group.